Everything below concerns DAC linker. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== Safety == Ammonium bicarbonate is an irritant to the skin, eyes and respiratory system. Short-term health effects may occur immediately or shortly after exposure to ammonium bicarbonate. Breathing ammonium bicarbonate can irritate the nose, throat and lungs causing coughing, wheezing and/or shortness of breath. Repeated exposure may cause bronchitis to develop with cough, and/or shortness of breath. Health effects can occur some time after exposure to ammonium bicarbonate and can last for months or years. Where possible, operations should be enclosed and the use of local exhaust ventilation at the site of chemical release is recommended. If local exhaust ventilation or enclosure is not used, respirators are necessary. Wear protective work clothing and change clothes and wash thoroughly immediately after exposure to ammonium bicarbonate. Ammonium bicarbonate from China used to make cookies was found to be contaminated with melamine, and imports were banned in Malaysia following the 2008 Chinese milk scandal.
== Decline == Insulin coma therapy was used in most hospitals in the US and the UK during the 1940s and 1950s. The numbers of patients were restricted by the requirement for intensive medical and nursing supervision and the length of time it took to complete a course of treatment. For example, at one typical large British psychiatric hospital, Severalls Hospital in Essex, insulin coma treatment was given to 39 patients in 1956. In the same year, 18 patients received modified insulin treatment, while 432 patients were given electroconvulsive treatment. In 1953, British psychiatrist Harold Bourne published a paper entitled "The insulin myth" in the Lancet, in which he argued that there was no sound basis for believing that insulin coma therapy counteracted the schizophrenic process in a specific way. If treatment worked, he said, it was because patients were chosen for their good prognosis and were given special treatment: "insulin patients tend to be an elite group sharing common privileges and perils". Prior to publishing "The insulin myth" in The Lancet, Bourne had tried to submit the article to the Journal of Mental Science; after a 12-month delay, the Journal informed Bourne they had rejected the article, telling him to "get more experience". In 1957, when insulin coma treatment use was declining, The Lancet published the results of a randomized, controlled trial in which patients were either given insulin coma treatment or identical treatment but with unconsciousness produced by barbiturates.
Another ancient way of preparing potatoes in the Andes was by mimicking native wildlife, specifically, wild relatives of the llama. They would lick clay before eating wild poisonous potatoes which would help negate the toxins. The people of the Andes copied this by creating a mixture of clay and water to dunk the potatoes into so they could eat them as well. The need for this mixture mostly disappeared with the selective breeding of non-poisonous potatoes but the practice remains in use where the old species of poisonous potatoes are still grown. Chuño is still produced in the Andean Altiplano, specifically in the Suni and Puna regions, which are the only regions with suitable eco-climatic conditions, and is consumed in Argentina, Bolivia, Chile and Peru. According to the botanist R.N. Salaman, in prehistoric times, chuño was ground into flour and incorporated into all kinds of stews and chupes, a kind of hearty soup of very ancient origin, but still cooked. Another traditional product of the Altiplano is tocosh, obtained from the fermentation of potatoes left in a stream of water for at least six months. This product, considered to have probiotic properties, is used in the preparation of a local dessert, the mazamorra de papas.
Sources: en.wikipedia.org
For big data analytics tools "to enter the public domain, work for the common good and not just for corporate interests, they need to be funded and developed by public organizations." The United Kingdom, Greece, and other national governments have already announced large investments in digital agriculture. Governments can also engage in private-public R&D partnerships to foster smallholder-oriented digital agriculture projects in developing countries. Lastly, digital agriculture technologies, particularly traceability systems, can improve monitoring of environmental compliance, evaluation of subsidy eligibility, etc. Finally, when governments and international undertake complementary investments, they can strengthen the enabling environment for digital agriculture. By improving digital infrastructure, choosing digital agriculture technologies appropriate for the regional context, and investing in human capital/digital skills development, policymakers could support digital agriculture.
== Structure == Drosophila contain a single Notch protein, C. elegans contain two redundant notch paralogs, Lin-12 and GLP-1, and humans have four Notch variants, Notch 1-4. Although variations exist between homologs, there are a set of highly conserved structures found in all Notch family proteins. The protein can broadly be split into the Notch extracellular domain (NECD) and Notch intracellular domain (NICD) joined together by a single-pass transmembrane domain (TM). The NECD contains 36 EGF repeats in Drosophila, 28-36 in humans, and 13 and 10 in C. elegans Lin-12 and GLP-1 respectively. These repeats are heavily modified through O-glycoslyation and the addition of specific O-linked glycans has been shown to be necessary for proper function. The EGF repeats are followed by three cysteine-rich Lin-12/Notch Repeats (LNR) and a heterodimerization (HD) domain. Together the LNR and HD compose the negative regulatory region adjacent to the cell membrane and help prevent signaling in the absence of ligand binding. NICD acts as a transcription factor that is released after ligand binding triggers its cleavage. It contains a nuclear localization sequence (NLS) that mediates its translocation to the nucleus, where it forms a transcriptional complex along with several other transcription factors. Once in the nucleus, several ankyrin repeats and the RAM domain interactions between the NICD and CSL proteins to form a transcriptional activation complex. In humans, an additional PEST domain plays a role in NICD degradation.
=== Personality === Her structural studies of biologically important molecules set standards for a field that was very much in development during her work life. She made contributions to the understanding of how these molecules carry out their tasks in living system.
Sources: en.wikipedia.org
=== Ergogenic aids === Ergogenic aids, or athletic performance-enhancing substances, include a number of drugs with various effects on physical performance. Drugs such as amphetamine and methylphenidate increase power output at constant levels of perceived exertion and delay the onset of fatigue, among other athletic-performance-enhancing effects; bupropion also increases power output at constant levels of perceived exertion, but only during short-term use.
== Role in diet == Scientists at the University of Manchester have discovered that hemopressin could be used as an appetite suppressant without having the side effects of many other drugs that are used for this purpose. In laboratory tests hemopressin was administrated to mice and rats, which significantly reduced food intake. Hemopressin works by affecting the reward centres of the brain which make us feel happy when we eat too much. A further research should be carried out in order to confirm these effects and the safety on people.
The adhesive strength from gastropod mucus has attracted scientific interest. The adhesive mucus is capable of bonding to wet surfaces chemically and physically by intertwining proteins and electrostatic attraction due to positively charged amines. Studies have also been conducted to discover antimicrobial properties in the glycoproteins in the mucus of certain snails like the Achatina fulica, or otherwise known as the African giant snail. Researchers look to the adhesive gastropod mucus to develop biomimetic hydrogels that can be used to heal incision wounds and as self-adhering micro-encapsulated drug carriers with antimicrobial properties.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.